Myoblast-mediated gene transfer to the joint

Area of Science:

• Biomedical Engineering
• Regenerative Medicine
• Gene Therapy

Background:

• Musculoskeletal conditions like arthritis and joint damage often require surgical intervention.
• Current gene therapy approaches using synovial cells show limited success due to transient transgene expression.
• Developing effective gene delivery vehicles for joint tissues is crucial for therapeutic advancements.

Purpose of the Study:

• To investigate muscle cells (myoblasts) as an alternative gene-delivery vehicle for intra-articular gene therapy.
• To compare the transduction efficiency of myoblasts versus synovial cells.
• To assess the in vivo behavior and gene expression duration of engineered myoblasts in joint tissues.

Main Methods:

• Adenoviral transduction of myoblasts and synovial cells in vitro.
• Intra-articular injection of engineered myoblasts into newborn rabbit and adult immunodeficient mouse knee joints.
• Assessment of myoblast adhesion, fusion into myotubes/myofibers, and reporter gene expression over time.

Main Results:

• Myoblasts exhibited higher transduction efficiency compared to synovial cells in vitro.
• Engineered myoblasts successfully adhered to various joint structures, including ligament, capsule, and synovium.
• Post-mitotic myotubes and myofibers formed in rabbit joints within 5 days, and reporter gene expression persisted for at least 35 days in mouse joints.

Conclusions:

• Muscle cells represent a viable and potentially superior gene-delivery vehicle for joint gene therapy.
• The formation of stable myofibers suggests the possibility of long-term therapeutic protein expression.
• This approach could offer a novel strategy for treating musculoskeletal disorders with poor healing capacity.